Allogene Therapeutics (ALLO)

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

ALLO stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
Low target
High target
Raymond James
5 May 22
Goldman Sachs
7 Mar 22

Investment data

Data from SEC filings
Securities sold
Number of investors


4 May 22
24 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 94.81M 94.81M 94.81M 94.81M 94.81M 94.81M
Cash burn (monthly) 29.6M 12.63M 26.66M 25.22M 22.75M 16.98M
Cash used (since last report) 52.57M 22.42M 47.36M 44.79M 40.4M 30.15M
Cash remaining 42.23M 72.38M 47.45M 50.02M 54.41M 64.65M
Runway (months of cash) 1.4 5.7 1.8 2.0 2.4 3.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 May 22 Amado Rafael Common Stock Sell Dispose S No No 7.3993 11,500 85.09K 546,257
31 Mar 22 Equity Holdings 2 B.V. PF Common Stock Other Dispose J No No 0 22,032,040 0 0
23 Mar 22 Veer Bhavnagri Common Stock Grant Acquire A No No 0 175,438 0 589,279
23 Mar 22 Veer Bhavnagri Stock Option Common Stock Grant Acquire A No No 9.69 272,435 2.64M 272,435
23 Mar 22 Schmidt Eric Thomas Common Stock Grant Acquire A No No 0 237,358 0 337,904
23 Mar 22 Schmidt Eric Thomas Stock Option Common Stock Grant Acquire A No No 9.69 368,589 3.57M 368,589
23 Mar 22 Moore Alison Stock Option Common Stock Grant Acquire A No No 9.69 737,179 7.14M 737,179
86.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 180 180
Opened positions 32 41 -22.0%
Closed positions 32 33 -3.0%
Increased positions 71 68 +4.4%
Reduced positions 43 43
13F shares Current Prev Q Change
Total value 1.16B 2.27B -48.9%
Total shares 124.56M 120.71M +3.2%
Total puts 79.6K 83.8K -5.0%
Total calls 119.3K 136.5K -12.6%
Total put/call ratio 0.7 0.6 +8.7%
Largest owners Shares Value Change
PFE Pfizer 22.03M $200.71M 0.0%
TPG GP A 18.72M $170.51M 0.0%
STT State Street 7.88M $71.77M +78.5%
BLK Blackrock 7.09M $64.56M +8.6%
Seaview Trust 7.04M $105.05M 0.0%
Vanguard 6.75M $61.53M +0.2%
Primecap Management 4.91M $44.7M +5.2%
Belldegrun Arie 4.71M $0 0.0%
TROW T. Rowe Price 4.27M $38.87M +31.2%
JPM JPMorgan Chase & Co. 3.56M $32.41M -1.8%
Largest transactions Shares Bought/sold Change
STT State Street 7.88M +3.46M +78.5%
Casdin Capital 0 -2.65M EXIT
Norges Bank 0 -1.63M EXIT
Capital World Investors 0 -1.3M EXIT
GS Goldman Sachs 2.96M +1.14M +62.5%
TROW T. Rowe Price 4.27M +1.02M +31.2%
Capital International Investors 587.08K -992.03K -62.8%
Renaissance Technologies 974.7K +974.7K NEW
Marshall Wace 0 -948.62K EXIT
Two Sigma Investments 954.16K +764.37K +402.7%

Financial report summary

  • We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*
  • Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.*
  • Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.
  • The COVID-19 global pandemic has and is adversely impacting our business, including our preclinical studies and clinical trials.*
  • We are heavily reliant on our partners for access to TALEN gene editing technology for the manufacturing and development of our product candidates.
  • Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.
  • Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.
  • Our product candidates may cause undesirable side effects or have other properties that have halted and could in the future halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*
  • Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.
  • Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may not be able to submit INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.
  • We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.
  • Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*
  • The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.
  • Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.
  • We may fail to successfully manufacture our product candidates, operate our own manufacturing facility, or obtain regulatory approval to utilize or commercialize from our manufacturing facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.
  • As a company, we have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.
  • A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*
  • We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*
  • We may form or seek additional strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • We may not realize the benefits of acquired assets or other strategic transactions.*
  • We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*
  • If our security measures, or those of our CROs, CMOs, collaborators, contractors, consultants or other third parties upon whom we rely, are compromised now, or in the future, or the security, confidentiality, integrity or availability of our information technology, software, services, networks, communications or data is compromised, limited or fails, we could experience a material adverse impact including, without limitation, a material interruption to our operations, including our
  • clinical trials, harm to our reputation, significant fines, penalties and liability, or a breach or triggering of data protection laws, privacy policies and data protection obligations.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.*
  • Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.
  • We are subject to stringent and changing privacy laws, regulations and standards as well as policies, contracts and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to enforcement or litigation (that could result in fines or penalties), a disruption of clinical trials or commercialization of products, reputational harm, or other adverse business effects.*
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
  • We rely on third parties to manufacture and store our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*
  • We rely on T cells from healthy donors to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted.
  • Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.*
  • If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.
  • The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
  • The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.*
  • The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.
  • We may be unable to obtain regulatory approval for ALLO-647 in a timely manner or at all, which could delay any approval or commercialization of our allogeneic T cell product candidates.
  • Regenerative Medicine Advanced Therapy designation and Fast Track designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.*
  • We plan to seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.
  • Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
  • Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.
  • The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.
  • We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
  • If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.
  • Confidentiality agreements with employees, Allogene Overland and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
  • Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.
  • We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • The lives of our patents may not be sufficient to effectively protect our products and business.
  • We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.
  • We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • Unstable market, economic and geo-political conditions may have serious adverse consequences on our business, financial condition and stock price.*
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
Management Discussion
  • Collaboration revenue was less than $0.1 million and $38.3 million for the three months ended March 31, 2022 and 2021, respectively. The decrease of $38.3 million was due to the revenue recognized related to the license of intellectual property and delivery of the know-how performance obligation, which was delivered in the first quarter of 2021, under the License Agreement entered into with Allogene Overland in December 2020.
  • Research and development expenses were $60.2 million and $55.2 million for the three months ended March 31, 2022 and 2021, respectively. The increase of $5.0 million was driven primarily by an increase in personnel related costs of $6.5 million, of which $3.2 million was stock-based compensation expense, and an increase in facilities costs and depreciation expense of $4.1 million, offset by a $6.7 million decrease in external costs relating to the advancement of our product candidates due to the timing of development activities and manufacturing runs.
  • General and administrative expenses were $19.9 million and $16.4 million for the three months ended March 31, 2022 and 2021, respectively. The increase of $3.5 million was primarily due to an increase in personnel related costs of $3.8 million, of which $2.4 million was stock-based compensation expense.

Content analysis

H.S. junior Avg
New words: accidental, alleviate, alteration, Antion, banning, bound, brain, built, caption, credential, deploying, disorder, draft, encryption, ERP, ESG, Extortion, flood, framework, FTD, geopolitical, Gilead, HQ, hypokinetic, Janssen, Johnson, LBCL, led, miCAR, military, miRNA, misconduct, modification, morale, multiplex, necessitate, network, neurocognitive, offline, online, outbreak, Parkinson, passed, PIPL, posture, PRC, retaliatory, Russia, silencing, stuffing, tool, tumor, UK, Ukraine, underwater, unlawful, unwilling, Utah, virulent
Removed: accurate, acted, active, Aid, American, analogy, applied, applying, ASC, behave, Biden, branded, compromise, consistently, CPPA, cyber, cyberattack, declared, demonstration, discontinuing, disruptive, domestic, dubbed, espionage, expedite, experiencing, extraterritorially, finalize, fiscal, gap, Goldman, Hematology, hostile, industrial, informally, Institute, interfere, intermediate, iv, legislation, marketable, methodology, minimum, Morgan, nonrefundable, optimize, outpatient, percent, pertaining, prescription, promise, rebate, reconsider, reexamining, reflecting, reflective, regime, registered, responsibility, reverse, robust, ruling, Society, subjected, supplying, surrogate, Topic, transferred, treated, unclear, undergo, unmet, usability, utilization, waiver, wire, wrongful